Core Viewpoint - Rosen Law Firm is encouraging investors of WPP plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1][3]. Group 1: Class Action Details - Investors who purchased WPP American Depositary Shares (ADS) between February 27, 2025, and July 8, 2025, may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by December 8, 2025, to be considered for lead plaintiff status [3][5]. - The complaint alleges that WPP misled investors by providing overly positive statements while concealing significant issues within its media arm, leading to substantial market share losses [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting experienced legal counsel, highlighting its track record in securities class actions and shareholder derivative litigation [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 8, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the Marex Group plc securities class action is from May 16, 2024, to August 5, 2025 [1]. - Investors who purchased Marex securities during this period may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 8, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements secured for investors [4]. Group 3: Allegations Against Marex - The lawsuit alleges that during the class period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - As a result of these actions, Marex's financial statements were deemed unreliable, leading to misleading positive statements about the company's business and operations [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by December 30, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [5] - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the company [5]

Group 1 - Trinity One Metals Ltd. has appointed Robert Payment as Director of the Company, who is currently serving as CFO and Corporate Secretary [1] - The Company announced the resignation of David Wheeler as director, effective immediately, and expressed gratitude for his contributions during his tenure [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Stride, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Stride securities between October 22, 2024, and October 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 12, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Stride made misleading statements about its products and services, inflating enrollment numbers and cutting staff costs beyond statutory limits [5]. - The firm claims that when the true details about Stride's operations became known, investors suffered damages [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of CarMax, Inc. to secure legal counsel before the January 2, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from June 20, 2025, to November 5, 2025 [2][6]. Summary by Sections Class Action Details - Investors who purchased CarMax securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 2, 2026 [4]. Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [5]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years [5]. Allegations Against CarMax - The lawsuit alleges that CarMax's management made materially false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [6]. - The claims suggest that when the true nature of the company's performance became known, investors suffered damages as a result of these misleading statements [6].

Group 1 - The article discusses the opportunity for stakeholders in the Mining and Metals industry to receive news releases via email, specifically mentioning Amex Exploration Inc. [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Incident Details - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the specified Class Period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's defendants misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].